REGENXBIO (RGNX)

Executive Summary

REGENXBIO (NASDAQ: RGNX) is a biotechnology company leveraging its proprietary NAV Technology Platform, a curated library of AAV vectors, to develop gene therapies for genetic diseases. The company's pipeline includes two key internal candidates: RGX-121 for Hunter syndrome (MPS II) and RGX-202 for Duchenne muscular dystrophy, both in clinical development. Additionally, REGENXBIO earns royalties from ZOLGENSMA, the first approved gene therapy for spinal muscular atrophy, co-developed with Novartis. The company's dual strategy of internal innovation and platform licensing to partners provides multiple value drivers. With a market cap of approximately $542 million, REGENXBIO is positioned to address significant unmet needs in rare diseases. Near-term focus includes advancing RGX-121 toward regulatory submission and generating clinical proof-of-concept for RGX-202, while expanding its NAV platform through new partnerships. The company faces typical biotech risks, including clinical trial outcomes and regulatory hurdles, but its established platform and past success with ZOLGENSMA underpin its potential.

Upcoming Catalysts (preview)

• Q3 2026RGX-121 BLA submission to FDA70% success
• Q4 2026RGX-202 Phase 2 interim efficacy data60% success
• H2 2026New NAV Technology platform licensing deal50% success